期刊文献+

Develop potential multi-target drugs by self-assembly of quercetin with amino acids and metal ion to achieve significant efficacy in anti-Alzheimer’s disease

原文传递
导出
摘要 Exploring multi-target drugs(MTDs)is a prevalent method against Alzheimer’s disease(AD).However,the current developed MTDs based on the“framework combination”technique or using flavonoids have not realized better healing effects owing to a complex metabolic process and low bioavailability.Here,we propose an alternative strategy to develop self-assembled nanoparticles(NPs)as MTDs using 9-fluorenylmethyloxycarbonyl-tryptophan(Fmoc-Trp),quercetin(Que),and Fe^(2+)as building blocks through coordination and electrostatic interaction to generate Fmoc-Trp-Fe^(2+)-Que(FTFQ)NPs.Whether in cell or in vivo,FTFQ NPs exhibited considerable biocompatibility attributing to the inherent biological affinity of assembly units.By combining the advantages of assemble approach and nanostructures,the obtained FTFQ NPs greatly enhanced the bioavailability of Que and displayed synergistic therapeutic effects through reducing Aβaggregation in direct/indirect means and eliminating the toxicity induced by ROS and Aβoligomer/fibrils.Furthermore,FTFQ NPs could obviously restore the AD zebrafish’s mobility and stimulus response ability.More importantly,developing self-assembly NPs as MTDs could be an efficient and general method to promote other novel MTDs by extending the assemble units to other drugs,peptides,and metal ions.Based on above benefits,these self-assembled NPs could be as potential MTDs and show great promising application in AD treatment.
出处 《Nano Research》 SCIE EI CSCD 2022年第6期5173-5182,共10页 纳米研究(英文版)
基金 supported by the National Natural Science Foundation(No.22076024) the Natural Science Foundation of Fujian Province(No.2021J01552) Fuzhou University Testing Fund of Precious Apparatus(No.2020T005).
  • 相关文献

参考文献4

二级参考文献51

  • 1Smith AG, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn) 2012; 18: 60-84.
  • 2Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60:108-11.
  • 3Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24: 1448-53.
  • 4Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011; 7: 573-83.
  • 5Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120: 1-34.
  • 6Vincent AM, Edwards JL, Sadidi M, Feldman EL. The antioxidant response as a drug target in diabetic neuropathy. Curr Drug Targets 2008; 9: 94-100.
  • 7Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-88.
  • 8Negi G, Kumar A, Joshi RP, Sharma SS. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle. Biochem Biophys Res Commun 2011; 408: 1-5.
  • 9Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res 2011; 50:124-31.
  • 10Kumar A, Sharma SS. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 394: 360-5.

共引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部